# Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) Subjects

> **NCT03591965** · PHASE2 · TERMINATED · sponsor: **Antengene Therapeutics Limited** · enrollment: 73 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** ATG-008

## Key facts

- **NCT ID:** NCT03591965
- **Lead sponsor:** Antengene Therapeutics Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-08-07
- **Primary completion:** 2022-08-03
- **Final completion:** 2022-08-03
- **Target enrollment:** 73 (ACTUAL)
- **Why stopped:** Based on the adjustment of clinical research and development strategy，sponsor decided to terminate the study
- **Last updated:** 2023-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03591965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03591965, "Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03591965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*